CAS 645-05-6|Altretamine
Introduction：Basic information about CAS 645-05-6|Altretamine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Altretamine | ||
|---|---|---|---|
| CAS Number | 645-05-6 | Molecular Weight | 210.279 |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 339.4±25.0 °C at 760 mmHg |
| Molecular Formula | C9H18N6 | Melting Point | 171-175 °C(lit.) |
| MSDS | ChineseUSA | Flash Point | 159.1±23.2 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | hexamethylmelamine |
|---|---|
| Synonym | More Synonyms |
Altretamine BiologicalActivity
| Description | Altretamine is an alkylating antineoplastic agent. |
|---|---|
| Related Catalog | Signaling Pathways >>Cell Cycle/DNA Damage >>DNA Alkylator/CrosslinkerResearch Areas >>Cancer |
| In Vitro | Altretamine is an antineoplastic agent[1]. |
| In Vivo | Altretamine (100, 133 mg/kg, ip.) in combination with Irofulven, increases the antitumor effect in mice bearing MV522 cells[1]. |
| Animal Admin | Mice[1] Balb/c nu/nu 4 week old female mice weighing 18-22 g, receive s.c. injections of 8-10 million MV522 cells. Altretamine is administered i.p. three times a week for 3 weeks, starting on day 10 after tumor implantation. Tumor size is measured in two perpendicular diameters and tumor weight (TW) estimated according to the formula: w = [(width)2 × length/2]. Altretamine is prepared as stock solutions of 1-10 mg/mL in 40% DMSO/normal saline and diluted with 10% DMSO/normal saline as required[1]. |
| References | [1]. Kelner MJ, et al. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. |
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 339.4±25.0 °C at 760 mmHg |
| Melting Point | 171-175 °C(lit.) |
| Molecular Formula | C9H18N6 |
| Molecular Weight | 210.279 |
| Flash Point | 159.1±23.2 °C |
| Exact Mass | 210.159302 |
| PSA | 48.39000 |
| LogP | 2.42 |
| Vapour Pressure | 0.0±0.7 mmHg at 25°C |
| Index of Refraction | 1.610 |
| InChIKey | UUVWYPNAQBNQJQ-UHFFFAOYSA-N |
| SMILES | CN(C)c1nc(N(C)C)nc(N(C)C)n1 |
| Storage condition | Refrigerator |
| Water Solubility | Insoluble |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human
- DOSE/DURATION :
- 8 mg/kg
- TOXIC EFFECTS :
- Gastrointestinal - nausea or vomiting Blood - leukopenia
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 350 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 265 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 437 mg/kg
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - chromodacryorrhea Blood - hemorrhage
- TYPE OF TEST :
- LD10 - Lethal Dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 200 mg/kg
- TOXIC EFFECTS :
- Blood - granulocytopenia Blood - changes in bone marrow (not otherwise specified)
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 171 mg/kg
- TOXIC EFFECTS :
- Cardiac - cardiomyopathy including infarction Liver - hepatitis (hepatocellular necrosis), zonal
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 100 mg/kg
- TOXIC EFFECTS :
- Blood - pigmented or nucleated red blood cells Blood - changes in leukocyte (WBC) count Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 255 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Bird - chicken
- DOSE/DURATION :
- 341 mg/kg
- TOXIC EFFECTS :
- Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - ataxia
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 3080 mg/kg/77D-I
- TOXIC EFFECTS :
- Gastrointestinal - changes in structure or function of endocrine pancreas Endocrine - hyperglycemia Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 625 mg/kg/5D-I
- TOXIC EFFECTS :
- Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 625 mg/kg/5D-I
- TOXIC EFFECTS :
- Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 250 mg/kg/5D-I
- TOXIC EFFECTS :
- Blood - changes in bone marrow (not otherwise specified) Blood - other changes Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 3108 mg/kg/3Y-I
- TOXIC EFFECTS :
- Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - leukemia
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 7 gm/kg/46W-C
- TOXIC EFFECTS :
- Tumorigenic - neoplastic by RTECS criteria Kidney, Ureter, Bladder - Kidney tumors Skin and Appendages - tumors
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1240 mg/kg
- SEX/DURATION :
- male 62 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 320 mg/kg
- SEX/DURATION :
- female 6-9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 320 mg/kg
- SEX/DURATION :
- female 9-12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1160 mg/kg
- SEX/DURATION :
- female 15-22 day(s) after conception lactating female 21 day(s) post-birth
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 80 mg/kg
- SEX/DURATION :
- female 15-22 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 780 mg/kg
- SEX/DURATION :
- female 6-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- TYPE OF TEST :
- Sex chromosome loss and nondisjunction
- TYPE OF TEST :
- Cytogenetic analysis
MUTATION DATA - TYPE OF TEST :
- DNA damage
- TEST SYSTEM :
- Mammal - species unspecified Lymphocyte
- DOSE/DURATION :
- 250 umol/L
- REFERENCE :
- CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 43,500,1983
- TYPE OF TEST :
- DNA damage
- TEST SYSTEM :
- Mammal - species unspecified Lymphocyte
- DOSE/DURATION :
- 250 umol/L
- REFERENCE :
- CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 43,500,1983
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R22;R36/37/38 |
| Safety Phrases | S26-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | OS1050000 |
| HS Code | 2933699090 |
Customs
| HS Code | 2933699090 |
|---|---|
| Summary | 2933699090 other compounds containing an unfused triazine ring (whether or not hydrogenated) in the structure。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:6.5%。General tariff:20.0% |
Articles34
More Articles| Chemical genetics reveals a complex functional ground state of neural stem cells. Nat. Chem. Biol. 3(5) , 268-273, (2007) The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain holds promise for the treatment of neurological diseases and has yielded new insight into brain canc... | |
| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J. Med. Chem. 51 , 6740-51, (2008) The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared ... | |
| FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 16 , 697-703, (2011) Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical trials and being withdrawn from the market. Comparative analysis of drugs based on their DILI potential is an effec... |
Synonyms
| HTM |
| 1,3,5-Triazine-2,4,6-triamine, N,N,N,N,N,N-hexamethyl- |
| Hexastat |
| 2,4,6-tris<dimethylamino>-1,3,5-triazine |
| HMM |
| N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine |
| Hexalen |
| EINECS 211-428-4 |
| N,N,N’,N’,N″,N″-hexamethyl-1,3,5-triazine-2,4,6-triamine |
| N,N,N',N',N'',N''-Hexamethyl-1,3,5-triazine-2,4,6-triamine |
| hexamethylmelamine |
| Altretamine |
| Hexylen |
| MFCD00549245 |
| N,N,N,N,N,N-Hexamethyl-1,3,5-triazine-2,4,6-triamine |
| NC 195 |
| hemel |
